Partnerships CEVEC is open to establish partnerships in order to broaden the use of its cell-based CAP technology. CEVEC's proprietary technology platform will be made available to other companies via license agreements. For further information about commercial or research licenses please contact Dr. Rainer Lichtenberger: lichtenberger@cevec-pharmaceuticals.com Wolfgang Kintzel: kintzel@cevec-pharmaceuticals.com

   Using CEVEC's proprietary technology, primary human amniocytes have been immortalized by adenoviral genetic E1/pIX functions and selected for highly efficient CAP (CEVEC's Amniocyte Production) Cell Lines. CAP (CEVEC's Amniocyte Production) Cell Lines contain adenovirus type 5 nucleotide sequence 505-4079 including the E1 genes and the entire pIX sequence.